Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Letters to the Editor

Ixazomib maintenance therapy in transplant-eligible multiple myeloma: real-world evidence from three large German centers

Department of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich
Department of Hematology, Oncology, and Stem-Cell Transplantation, University Hospital Freiburg, Albert Ludwig University of Freiburg, Germany; Comprehensive Cancer Center Freiburg
Department of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich
Department of Medicine III, LMU University Hospital, Ludwig-Maximilians-University Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Bavarian Cancer Research Center (BZKF)
Department of Hematology, Oncology, and Stem-Cell Transplantation, University Hospital Freiburg, Albert Ludwig University of Freiburg, Germany; Comprehensive Cancer Center Freiburg
Department of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Germany; Center for Personalized Medicine, TUM University Hospital, Technical University of Munich
Hematology and Oncology Munich-Pasing Medical Care Centre GmbH (MVZ), Munich
Department of Medicine III, LMU University Hospital, Ludwig-Maximilians-University Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Bavarian Cancer Research Center (BZKF)
Department of Hematology, Oncology, and Stem-Cell Transplantation, University Hospital Freiburg, Albert Ludwig University of Freiburg, Germany; Comprehensive Cancer Center Freiburg
Department of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Bavarian Cancer Research Center (BZKF), Germany; TranslaTUM, Center for Translational Cancer Research, Technical University of Munich
Department of Internal Medicine III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Germany; Comprehensive Cancer Center Munich (CCCM), Germany; German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany; Center for Personalized Medicine, TUM University Hospital, Technical University of Munich, Germany; Department of Hematology and Medical Oncology, University Medical Center Göttingen
Haematologica Early view Oct 16, 2025 https://doi.org/10.3324/haematol.2025.288320

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor
 
DOI
https://doi.org/10.3324/haematol.2025.288320
Pubmed
41098101
 
Published
2025-10-16
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2025 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
540
PDF Downloads
296

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2025 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online